Cargando…
Successful use of tPA for thrombolysis in COVID related ARDS: a case series
We describe successful usage of low dose Tissue plasminogen activator (tPA) (30–50 mg) in three COVID19 critically ill patients, who were in worsening respiratory failure in-spite of being on therapeutic anticoagulation. All patients had respiratory rate > 40; FiO(2) > 0.7(on NIV); PiO(2)/FiO(...
Autores principales: | Goyal, Abhishek, Saigal, Saurabh, Niwariya, Yogesh, Sharma, Jaiprakash, Singh, Pooja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330540/ https://www.ncbi.nlm.nih.gov/pubmed/32617806 http://dx.doi.org/10.1007/s11239-020-02208-2 |
Ejemplares similares
-
tPA or not tPA? Lysis therapy in the setting of COVID‐19 and ECMO
por: Cromartie, Anjelica, et al.
Publicado: (2022) -
Outcomes of Patients Requiring Blood Pressure Control Before Thrombolysis with tPA for Acute Ischemic Stroke
por: Darger, Bryan, et al.
Publicado: (2015) -
Assessment of Obstructive Sleep Apnea in Association with Severity of COVID-19: A Prospective Observational Study
por: Kar, Avishek, et al.
Publicado: (2021) -
Analyses on safety and efficacy of non-standard dose of r-tPA in intravenous thrombolysis-treated AIS patients
por: Yuan, Jiawen, et al.
Publicado: (2022) -
The safety and efficacy of tPA intravenous thrombolysis for treating acute ischemic stroke patients with a history of cerebral hemorrhage
por: Zhao, Guang-jian, et al.
Publicado: (2019)